Elite Pharmaceuticals announced the commercial launch of its generic methadone hydrochloride 5 mg and 10 mg tablets, a product line aimed at managing severe and persistent pain as well as detoxification and maintenance treatment for opioid addiction.
The launch taps into a U.S. retail market that reached approximately $22 million in 2025, a figure that underscores the modest but meaningful revenue opportunity for a company that operates in a high‑barrier, DEA‑regulated space.
Elite’s strategy to grow its direct‑sales model is reinforced by the new product, which will be manufactured at the company’s cGMP‑certified, DEA‑registered facility in Northvale, New Jersey. The controlled‑substance portfolio expansion aligns with the company’s focus on niche generics with high entry barriers.
Financially, the launch comes as Elite reported Q3 fiscal 2026 revenue of $31.6 million, up 119.9% year‑over‑year, and a net income of $18.6 million, a turnaround from a $10.9 million loss in the same quarter a year earlier. Gross margin fell to 41% from 43% in the prior year, a dip attributed to a higher proportion of indirect sales through wholesalers and the elimination of one‑time costs associated with earlier product introductions.
On the announcement day, the company’s shares rose 4.95%, reflecting investor confidence that the new product will add a meaningful revenue stream while the company continues to manage margin pressure through its direct‑sales focus.
The launch demonstrates Elite’s ability to leverage its specialized manufacturing capabilities and strategic focus on controlled‑substances, positioning the company for continued growth in a market that remains critical to pain management and opioid addiction treatment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.